-- カルティエ・リソーシズ（ECR.V）は木曜日、同社の株式がOTCQBベンチャー市場でティッカーシンボルECRFFで取引開始されたと発表した。 同社は引き続きトロント証券取引所ベンチャー市場（TSX Venture Exchange）でもティッカーシンボルECRで取引される。 カルティエ・リソーシズの社長兼最高経営責任者（CEO）であるフィリップ・クルーティエ氏は、「OTCQBへの上場は、当社の成長戦略における重要な一歩であり、米国投資家の間での認知度向上、取引流動性の改善、米国資本市場へのアクセス拡大につながると期待しています。また、プロジェクト推進と長期的な成長目標達成に向けて、投資家とのエンゲージメント強化にも貢献すると考えています」と述べた。 同社の株価は、TSX Venture Exchangeで0.245ドルで横ばいだった。
Related Articles
Mining & Metals
Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share
$AEM.TO
Treasury
TD Bank Group Issues 150 Million Swiss francs Green Bond
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
$TD$TD.TO
Research
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
$AMGN